A is the ticker symbol for AGILENT TECHNOLOGIES, INC., a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks A with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is A a good stock to buy?

13F Pro's AI ranking engine scores A at 67.6/100, ranked #356 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for A is available at https://13fpro.ai/company/A. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source A data?

All AGILENT TECHNOLOGIES, INC. fundamentals and ownership data come directly from SEC EDGAR. AGILENT TECHNOLOGIES, INC. files with the SEC under CIK 1090872. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

AGILENT TECHNOLOGIES, INC. A

NYSELarge CapHealthcare

13F Pro quality score

Rank #356 of 2,925TOP 25%

Why it scores 68 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.88B

Quarter to Jul 31

Net income

$362.00M

Quarter to Jul 31

Free cash flow

$439.00M

Quarter to Jul 31

Operating margin

23.6%

Quarter to Jul 31

Top Institutional Holders

as of Q2 2026

$34.52B total

BlackRock, Inc.

$3.40B-1.2%

VANGUARD CAPITAL MANAGEMENT LLC

$2.45B+0.4%

VANGUARD PORTFOLIO MANAGEMENT LLC

$1.92B+0.6%

STATE STREET CORP

$1.71B+0.7%

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

$1.36B-20.7%

T. Rowe Price Investment Management, Inc.

$1.03B-13.7%

GEODE CAPITAL MANAGEMENT, LLC

$1.00B+1.0%

WELLINGTON MANAGEMENT GROUP LLP

$990.21M+2.7%

DEUTSCHE BANK AG\

$930.96M+17.1%

Bank of New York Mellon Corp

$695.23M+87.4%

MORGAN STANLEY

$688.82M+4.8%

FMR LLC

$674.27M+453.7%

GOLDMAN SACHS GROUP INC

$625.33M+31.6%

Pictet Asset Management Holding SA

$596.98M+28.5%

NORGES BANK

$513.99M--

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO

$508.11M0.0%

NORTHERN TRUST CORP

$490.40M-0.2%

AQR CAPITAL MANAGEMENT LLC

$472.36M+20.4%

Invesco Ltd.

$377.67M+22.9%

Troy Asset Management Ltd

$355.54M+10.9%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$338.02M-3.8%

NORDEA INVESTMENT MANAGEMENT AB

$310.81M+0.2%

JPMORGAN CHASE & CO

$306.75M-0.5%

DIMENSIONAL FUND ADVISORS LP

$306.40M+9.4%

FIRST TRUST ADVISORS LP

$276.23M+164.6%

See all 1,138 institutional holders →

What's Driving A's Business? Latest 10-Q Breakdown

24/24 datapoints verified

AI-extracted from the 10-Q filed 2026-09-01 — Q3 FY2026 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Agilent reported Q3 revenue of $1.88B (+8% YoY) with net income of $362M, while acquiring Biocare for $950M to expand its pathology portfolio.

Biggest Revenue Drivers

Agilent CrossLab$786M+6% YoY

Services and consumables portfolio; strong growth in repair, maintenance, compliance services and consumables businesses across pharmaceutical and chemical markets.

Life Sciences and Diagnostics Markets$746M+11% YoY

Strong revenue growth from liquid chromatography, Agilent Advanced Therapeutics, consumables and genomics businesses; includes Biocare acquisition contribution.

Biggest Revenue Drivers

Total revenue: $1,878M+8% YoY

Agilent CrossLab$786M+6% YoY

Services and consumables portfolio; strong growth in repair, maintenance, compliance services and consumables businesses across pharmaceutical and chemical markets.

Life Sciences and Diagnostics Markets$746M+11% YoY

Strong revenue growth from liquid chromatography, Agilent Advanced Therapeutics, consumables and genomics businesses; includes Biocare acquisition contribution.

Applied Markets$346M+7% YoY

Strong growth in chemical and advanced materials market driven by spectroscopy, gas chromatography, remarketed instruments and vacuum businesses.

Largest Expense Items

Cost of products and services$836M-1% YoY

Higher sales volume and tariff refunds offset by wage increases and higher variable pay.

Selling, general and administrative$475M+14% YoY

Higher costs from transformational initiatives, variable pay, wage increases and unfavorable currency impact.

Research and development$123M+10% YoY

Higher costs from transformational initiatives, wage increases and higher variable pay partially offset by restructuring savings.

Margins: Gross margin improved 4 percentage points to 55.5%, driven by higher sales volume, net tariff refunds, price increases and favorable mix, partially offset by wage and variable pay increases. Operating margin expanded 3 percentage points to 23.6%, benefiting from gross margin expansion and lower restructuring costs despite higher transformational initiative expenses.

Watch Items from the Filing

Biocare acquisition on June 24, 2026 for $950M net cash consideration adds $549M goodwill and $520M intangible assets, representing material integration risk and synergy execution dependency.
Tariff situation remains dynamic with only de minimis net benefit (~1 ppt margin lift) from IEEPA refunds; future refund timing and approval uncertain pending legal and regulatory developments.
Inventory days on hand increased to 120 days from 107 days YoY due to strategic tariff mitigation purchases, tying up $110M in cash flow YTD.
FY26 and FY25 restructuring plans total $124M cumulative expense with expected annual savings of $120M–$130M once completed; execution risk on realizing full benefit.
Academic and government market revenue declined; this end-market showed weakness across Life Sciences and Agilent CrossLab segments despite overall company growth.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q3 2026

EDGAR

Net Income

Q3 2026

EDGAR

EPS (Diluted)

Q3 2026

EDGAR

Operating Margin

Q3 2026

EDGAR

ROIC

Q3 2026

EDGAR

Free Cash Flow

Q3 2026

EDGAR

Debt/Equity

Q3 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/A

Earnings Per Share

13fpro.ai/company/A

Loading ratio trend…

AGILENT TECHNOLOGIES, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$6.9B	$1.3B	21.3%
FY 2024	10-K	$6.5B	$1.3B	22.9%
FY 2023	10-K	$6.8B	$1.2B	19.8%
FY 2022	10-K	$6.8B	$1.3B	23.6%
FY 2021	10-K	$6.3B	$1.2B	21.3%
FY 2020	10-K	$5.3B	$719.0M	15.8%

About AGILENT TECHNOLOGIES, INC. (A): stock profile, AI score and financials

AGILENT TECHNOLOGIES, INC. (A) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores A at 67.6/100 on a composite quality score built from its SEC filings, placing it at rank #356 of 2,925 stocks — the top 25% of the AI-ranked universe. A scores in the top quartile across balance sheet strength (87.2), revenue scale (83.0), profitability (80.4). Shareholder dilution risk is elevated at 40.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), AGILENT TECHNOLOGIES, INC. reports quarterly revenue of $1.9B, net income of $362.0M, an operating margin of 23.6%. Top institutional holders of A by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. A trades on the NYSE exchange and files with the SEC under CIK 1090872. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate A daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AGILENT TECHNOLOGIES, INC. directly from SEC EDGAR.

Financials through the period ended Jul 31, 2026SEC EDGAR: CIK 1090872 →

AGILENT TECHNOLOGIES, INC. A

Top Institutional Holders

What's Driving A's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

A key financials by period

A insiders

Congress trading in A

About AGILENT TECHNOLOGIES, INC. (A): stock profile, AI score and financials

AGILENT TECHNOLOGIES, INC. A

Top Institutional Holders

What's Driving A's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

A key financials by period

Companies similar to A

A insiders

Congress trading in A

About AGILENT TECHNOLOGIES, INC. (A): stock profile, AI score and financials